Literature DB >> 16103075

Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas.

Yasunori Shikada1, Yoshikazu Yonemitsu, Takaomi Koga, Mitsuho Onimaru, Toshiaki Nakano, Shinji Okano, Shihoko Sata, Kazunori Nakagawa, Ichiro Yoshino, Yoshihiko Maehara, Katsuo Sueishi.   

Abstract

It is widely accepted that angiogenesis is required for tumor progression. Vascular endothelial growth factor (VEGF) is a key molecule for tumor angiogenesis; however, its expressional regulation is not well understood during all stages of tumorigenesis. Using cell lines and surgical specimens of human non-small cell lung cancers (NSCLCs), we here show that platelet-derived growth factor-AA (PDGF-AA) is an essential autocrine regulator for VEGF expression. To directly assess the expression of PDGF-AA-dependent VEGF and its roles in tumorigenesis, we stably transfected established cell lines with their antisense genes. In addition, the levels of PDGF-AA and VEGF expression in surgical sections were measured and compared with clinicopathologic findings such as tumor size and patient prognosis. PDGF-AA tightly regulated VEGF expression and had a greater effect on tumor size and patient prognosis than did VEGF in both cell lines and surgical sections. PDGF-AA expression was not seen in the atypical adenomatous hyperplasia at all, whereas VEGF was occasionally seen. Furthermore, the frequency of VEGF expression was higher in advanced NSCLCs than in precancerous lesions, which was tightly correspondent to the results for PDGF-AA. These results indicate that PDGF-AA is an important regulator of the frequency and level of VEGF expression during the transition from a precancerous lesion to advanced cancer. The PDGF-AA/VEGF axis, therefore, may be a ubiquitous autocrine system for enhancing angiogenic signals, and PDGF-AA, and its related pathways could be a more efficient target of antiangiogenic therapy for cancers than VEGF and its pathways.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103075     DOI: 10.1158/0008-5472.CAN-04-4171

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

Review 1.  New treatment options for lung adenocarcinoma--in view of molecular background.

Authors:  Nora Bittner; Gyula Ostoros; Lajos Géczi
Journal:  Pathol Oncol Res       Date:  2013-12-05       Impact factor: 3.201

2.  Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer.

Authors:  Anne S Tsao; Wei Wei; Elisabetta Kuhn; Loreto Spencer; Luisa M Solis; Milind Suraokar; J Jack Lee; Waun Ki Hong; Ignacio I Wistuba
Journal:  Clin Lung Cancer       Date:  2011-05-17       Impact factor: 4.785

Review 3.  Paraneoplastic syndromes associated with lung cancer.

Authors:  Nobuhiro Kanaji; Naoki Watanabe; Nobuyuki Kita; Shuji Bandoh; Akira Tadokoro; Tomoya Ishii; Hiroaki Dobashi; Takuya Matsunaga
Journal:  World J Clin Oncol       Date:  2014-08-10

4.  Peripheral Blood-Derived Mesenchymal Stromal Cells Promote Angiogenesis via Paracrine Stimulation of Vascular Endothelial Growth Factor Secretion in the Equine Model.

Authors:  Leen Bussche; Gerlinde R Van de Walle
Journal:  Stem Cells Transl Med       Date:  2014-10-13       Impact factor: 6.940

5.  Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population.

Authors:  Gu Ping; Wang Hui-Min; Wang Wei-Min; Han Bao-Hui
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

6.  Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells.

Authors:  Masaki Matsuura; Mitsuho Onimaru; Yoshikazu Yonemitsu; Hanako Suzuki; Toshiaki Nakano; Hiroaki Ishibashi; Kanemitsu Shirasuna; Katsuo Sueishi
Journal:  Am J Pathol       Date:  2009-09-24       Impact factor: 4.307

Review 7.  Targeting angiogenesis in squamous non-small cell lung cancer.

Authors:  Bilal Piperdi; Amartej Merla; Roman Perez-Soler
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

8.  Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

Authors:  Mark A Socinski; Silvia Novello; Julie R Brahmer; Rafael Rosell; Jose M Sanchez; Chandra P Belani; Ramaswamy Govindan; James N Atkins; Heidi H Gillenwater; Cinta Pallares; Lesley Tye; Paulina Selaru; Richard C Chao; Giorgio V Scagliotti
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

9.  Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer.

Authors:  S Novello; G V Scagliotti; R Rosell; M A Socinski; J Brahmer; J Atkins; C Pallares; R Burgess; L Tye; P Selaru; E Wang; R Chao; R Govindan
Journal:  Br J Cancer       Date:  2009-10-13       Impact factor: 7.640

10.  Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.

Authors:  Kusumawadee Utispan; Peti Thuwajit; Yoshimitsu Abiko; Komgrid Charngkaew; Anucha Paupairoj; Siri Chau-in; Chanitra Thuwajit
Journal:  Mol Cancer       Date:  2010-01-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.